Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Greenwich Lifesciences Inc (GLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $39
1 Year Target Price $39
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 134.08M USD | Price to earnings Ratio - | 1Y Target Price 39 |
Price to earnings Ratio - | 1Y Target Price 39 | ||
Volume (30-day avg) 1 | Beta 3.25 | 52 Weeks Range 8.06 - 17.19 | Updated Date 07/4/2025 |
52 Weeks Range 8.06 - 17.19 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -253.55% | Return on Equity (TTM) -515.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 131334130 | Price to Sales(TTM) - |
Enterprise Value 131334130 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 13368300 | Shares Floating 6112523 |
Shares Outstanding 13368300 | Shares Floating 6112523 | ||
Percent Insiders 52.3 | Percent Institutions 9.47 |
Upturn AI SWOT
Greenwich Lifesciences Inc
Company Overview
History and Background
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences. Founded to address unmet needs in breast cancer treatment, the company has primarily focused on advancing its GP2 clinical program.
Core Business Areas
- GP2 Immunotherapy Development: The core business focuses on the development and clinical trials of GP2, a HER2/neu peptide designed to stimulate the patient's immune system to target and destroy residual cancer cells, potentially preventing recurrence in HER2/neu positive breast cancer patients.
Leadership and Structure
Greenwich LifeSciences is led by a management team with experience in biotechnology and clinical development. The company structure is typical of a small, clinical-stage biotech, with emphasis on research, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- GP2: GP2 is Greenwich LifeSciences' lead product candidate, an immunotherapy designed to prevent breast cancer recurrence. It is currently in Phase III clinical trials. Market share data is not applicable as the product is not yet approved for commercial sale. Competitors include companies developing other breast cancer therapies, such as Roche/Genentech (Herceptin, Perjeta, Kadcyla), and Puma Biotechnology (Nerlynx). Once approved, GP2 would compete in the adjuvant breast cancer treatment market.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant R&D investment and stringent regulatory oversight. The breast cancer therapeutics market is substantial and growing, driven by increased incidence and improved diagnosis. The focus is on targeted therapies and immunotherapies.
Positioning
Greenwich LifeSciences aims to position GP2 as a novel immunotherapy for preventing breast cancer recurrence. Its competitive advantage, if clinical trials are successful, would be offering a new approach compared to standard treatments. It is a relatively small company seeking to disrupt the existing adjuvant treatment landscape.
Total Addressable Market (TAM)
The total addressable market for adjuvant breast cancer therapies is significant, estimated in the billions of dollars annually. Greenwich LifeSciences is positioned to capture a portion of this market with GP2, if approved, targeting HER2/neu positive patients post-surgery. The TAM can be estimated using annual cancer diagnoses and prevalence rates.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Potential to address unmet need in preventing breast cancer recurrence
- Focused development of GP2
Weaknesses
- Reliance on a single product candidate (GP2)
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risk and regulatory hurdles
Opportunities
- Successful completion of Phase III clinical trials
- Partnership with larger pharmaceutical companies
- Expansion of GP2's application to other HER2/neu expressing cancers
Threats
- Clinical trial failure
- Regulatory disapproval
- Competition from existing and emerging therapies
- Inability to secure sufficient funding
Competitors and Market Share
Key Competitors
- ROCHE (ROG.SW)
- PBYI (PBYI)
Competitive Landscape
Greenwich LifeSciences is a small player competing against larger pharmaceutical companies with established breast cancer therapies. Its advantage lies in its novel immunotherapy approach, but faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Greenwich LifeSciences' growth is tied to the progress of GP2 through clinical trials. The company has shown growth potential contingent on successful clinical data.
Future Projections: Future growth depends on the successful commercialization of GP2. Analyst projections are based on estimated market penetration and pricing assumptions.
Recent Initiatives: Recent initiatives include advancing the Phase III clinical trial of GP2 and seeking potential partnerships.
Summary
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focusing on GP2, a novel immunotherapy for breast cancer recurrence prevention. The company's strength lies in its innovative approach, but it faces significant risks associated with clinical trials and competition from established therapies. Success hinges on positive Phase III trial results and securing adequate funding for commercialization. It needs to look out for potential trial failures and ensure sufficient capital to operate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Greenwich Lifesciences Inc
Exchange NASDAQ | Headquaters Stafford, TX, United States | ||
IPO Launch date 2020-09-25 | CEO, CFO & Director Mr. Snehal S. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.